Education
About Us
Working with TipRanks
Follow Us
CSPC Pharmaceutical Group Limited (CHJTF)
OTHER OTC:CHJTF
CHJTF Stock Chart & Stats
$0.96
>-$0.01(-0.77%)
At close: 4:00 PM EST
$0.96
>-$0.01(-0.77%)
Day’s Range― - ―
52-Week Range$0.52 - $1.41
Previous CloseN/A
Volume389.00
Average Volume (3M)14.41K
Market Cap
$12.21B
Enterprise Value$80.96B
Total Cash (Recent Filing)$10.63B
Total Debt (Recent Filing)$495.00M
Price to Earnings (P/E)20.7
Beta0.30
Next Earnings
Mar 25, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend Yield3.2%
Share Statistics
EPS (TTM)0.01
Shares Outstanding11,522,452,000
10 Day Avg. Volume2,182
30 Day Avg. Volume14,414
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)1.63
Price to Sales (P/S)1.90
P/FCF Ratio30.23
Enterprise Value/Market Cap6.63
Enterprise Value/Revenue2.97
Enterprise Value/Gross Profit4.46
Enterprise Value/Ebitda12.05
Forecast
1Y Price Target
$1.39Price Target Upside44.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cost ManagementThe selling expense ratio has significantly decreased, indicating improved cost management and potential for better profitability.
Earnings GrowthCSPC's BD deals are expected to be a key sustainable driver of earnings growth.
Out-licensing AgreementsCSPC has signed six out-licensing agreements across a diverse portfolio of assets, indicating a strong out-licensing potential that could drive sustainable income.
Bears Say
Revenue DeclineCore revenue, excluding business development income, has decreased by 19% year-over-year, reflecting challenges in sustaining sales growth.
CSPC Pharmaceutical Group News
CHJTF FAQ
What was CSPC Pharmaceutical Group Limited’s price range in the past 12 months?
CSPC Pharmaceutical Group Limited lowest stock price was $0.52 and its highest was $1.41 in the past 12 months.
What is CSPC Pharmaceutical Group Limited’s market cap?
CSPC Pharmaceutical Group Limited’s market cap is $12.21B.
When is CSPC Pharmaceutical Group Limited’s upcoming earnings report date?
CSPC Pharmaceutical Group Limited’s upcoming earnings report date is Mar 25, 2026 which is in 90 days.
How were CSPC Pharmaceutical Group Limited’s earnings last quarter?
CSPC Pharmaceutical Group Limited released its earnings results on Nov 20, 2025. The company reported $0.011 earnings per share for the quarter, missing the consensus estimate of $0.017 by -$0.005.
Is CSPC Pharmaceutical Group Limited overvalued?
According to Wall Street analysts CSPC Pharmaceutical Group Limited’s price is currently Undervalued.
Does CSPC Pharmaceutical Group Limited pay dividends?
CSPC Pharmaceutical Group Limited pays a Semiannually dividend of $0.018 which represents an annual dividend yield of 3.2%. See more information on CSPC Pharmaceutical Group Limited dividends here
What is CSPC Pharmaceutical Group Limited’s EPS estimate?
CSPC Pharmaceutical Group Limited’s EPS estimate is 0.02.
How many shares outstanding does CSPC Pharmaceutical Group Limited have?
CSPC Pharmaceutical Group Limited has 11,522,452,000 shares outstanding.
What happened to CSPC Pharmaceutical Group Limited’s price movement after its last earnings report?
CSPC Pharmaceutical Group Limited reported an EPS of $0.011 in its last earnings report, missing expectations of $0.017. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CSPC Pharmaceutical Group Limited?
Currently, no hedge funds are holding shares in CHJTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSPC Pharmaceutical Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.69%
12-Months-Change
Fundamentals
Return on Equity
11.30%
Trailing 12-Months
Asset Growth
-2.61%
Trailing 12-Months
Company Description
CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
CHJTF Stock 12 Month Forecast
Average Price Target
$1.39
▲(44.79% Upside)
Technical Analysis
Sino Biopharmaceutical
―
Innovent Biologics
―
Sinopharm Group Co
―
Wuxi Biologics (Cayman)
―
Hansoh Pharmaceutical Group Company Limited
―
Ownership Overview
―
Insiders
4.26% Mutual Funds
― Other Institutional Investors
88.18% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---